Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEBT-209 in Women With Advanced Breast Cancer
NCT06047184Phase 1Completed
- Sponsor
- BeBetter Med
- Start
- Jul 2019
- Primary completion
- Jan 2024
- Countries
- 1
01
Overview
Phase 1, open-label trial of bebt-209 in breast cancer (10 arms), sponsored by BeBetter Med. Primary endpoints: Maximum Tolerated Dose at 4 weeks and Dose-Limiting Toxicity at 4 weeks. Started Jul 2019; status: completed.
02
Drugs
bebt-209
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06047184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06047184.